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ABSTRACT 
Three patients, one male and two females who developed neuroleptic malignant syndrome following 
exposure to depot and oral neuroleptic are presented. The patients satisfied Levenson's criteria for diagnosis. 
Bromocriptine and Electro Convulsive Therapy were found effective whereas trihexyphenidyl proved unsatisfactory 
in the treatment. All the patients recovered completely without complications. 
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INTRODUCTION 
The neuroleptic malignant syndrome was 
first described by Delay and Deniker in 1968. 
Initially thought to be rare, Neuroleptic Malignant 
Syndrome (NMS) is now more frequently re-
ported in patients treated with butyrophenones 
andphenothiazines (Singh, 1981;Levenson, 1985; 
Rurien et al, 1993). Besides neuroleptics, non-
neuroleptic pharmacotherapy has also been known 
to produce NMS (Kurlan et al, 1984; Guze and 
Baxter, 1985). The diagnostic criteria proposed 
by Levenson in 1985 have been used in selecting 
cases and use of anti-cholinergics, dopamine-
agonist and Electro Convulsive Theerapy (ECT) 
in the treatment of NMS is described. 
CASE REPORTS 
The socio- demographic data, primary di-
agnosis and treatment information of the three 
cases is given in Table-I. All the three patients 
had fever, rigidity, altered consciousness- one 
patient had fluctuating blood pressure and unex-
plained sweating, suggesting autonomic imbal-
ance. 
The clinical details are given in Table 2.0ne 
patient in addition also had tubercular pleural 
effusion. All the patients were discharged with-
out complications. The treatment was directed 
at withdrawal of offending drug and precipitating 
causes like dehydration. Specific threapy for the 
condition was initiated at the earliest and contin-
ued till the muscle rigidity completely subsided. 
DISCUSSION : 
The incidence of NMS has varied in liter-
ature from 0.02 per cant to 3.23 per cent 
(Lazarus et al, 1989). Fever , rigidity and raised 
Creatinine Phosphokinase (CPK)*have been la-
belled major criteria and tachycardia, tachypnoea 
altered mental state, abnormal B.P., diaphoresis 
and leucoytosis as minor criteria (Levenson 1985). 
For diagnosis, the presence of all the 3 major 
criteria or 2 major with all the minor criteria has 
been suggested. 
In the first case where NMS developed 
after flupenthixol injections, after intial improve-
ment with trihexyphenidyl (THP) and 
promethazine, the symptoms worsened. 
Promethazine, resolved all the symptoms mark-
edly though it took nearly 6 weeks for complete 
recovery. Similar delay in recovery has been 
described in patients receiving depot neuroleptics 
(Greenberg and Gujavarty, 1985; Deng et al, 
1990) Symptoms like strong desire to cry, rest-
lessness and insomnia after a few days of 
therapy of bromocriptine are consistent with its 
dopamine agonistic activity in limbic path ways. 
100 TABLE I 
AGE, SEX, PRIMARY DIAGNOSIS, NEUROLEPTICS, DURATION OF NEUROLEPTIC 
TREATMENT, SPECD7IC TREATMENT, RESPONSE. HOSPITAL STAY, COMPLICATION AND 
OUTCOME. 
Case Age Sex Primary Neuroleptics Duration of Specific Other Response Hospital Complications Outcome 
No. (In Years) Diagnosis Neuroleptic treatment treatment stay 
I 55  F Unipolar Flupenthlxol 7 days Trihexyphenidyl Supportive Inadequate 15 days Sacral sore Complete 
depression depot 20 rag 
!/M Injection 
6mg/day 
Promethazine 
HCL 
150 mg/day 
Bromocriptine 
1S.5 mj/day 
Inadequate 
Marked 
recovery 
18 F Mania Haloperidoi 7 days Trihexyphenidyl Supportive Inadequate 
15-30mg/day 6mg/day 
Promethazine 
HCL 
150 mg/day 
Diazepam 
lOmg/day 
Elecl/o 
convulsive 
Therapy (Total-6) 
Inadequate 20 days NIL 
Inadequate 
Marked 
Complete 
Schlzo TrUhiperazlne 9 days Trihexlphenidyl Supportive Significant 30 days NIL 
phenla 15 mg/day 6-8 mg/day and ATT 
with 
Tubercular 
Pleural 
effusion 
Complete 
recovery 
TABLE-H 
DIAGNOSTIC FEATURES IN THREE CASES 
Case Maximum Muaclc Mental [Ail**- KrspiisUon III' Dlaphuicals Tremors Inrotit TI.C CVK Criteria 
No. temperature ri^rltty state rate rate per mtn Intiitx-
1 10l"K Prof'iuIHl Slupo,o«c IZO/ml 24 
2 101"F Swnr Drowsy 124/int 20 
:i 100"F Severe Drowsy 100/uit 22 
1KO/10O 
nun Hg 
I40/9U 
mm llg 
100/70 <• • • 
mm Hx 
12000/t-nim IV) III/I MJ 3 MN 5 
|].400An«n 123 "71 Ml .1 MN-4 
12.500/cHan 200 1U/I M.I 1 MN 4 
*M.l Major and MN-Mlnor criteria full filled. 
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In the second case, ECT proved very useful in 
treating NMS. However due to poor response to 
THP in the first two cases and prolonged recov-
ery time in this case, the possibility of natural 
recovery cannot he excluded. Spontaneous re-
covery and varible treatment response to THP in 
NMS has been described (Weinberger and Kelly, 
1977 Henderson and Wosten , 1981). 
Pre-disposing factors which have been im-
plicated in the syndrome include discontinuation 
of dopanune agonists, anti-parkinsonian drugs 
(Fricndman et al, 1985), use of dopamine deplet-
ing drugs (Henderson and Wosten , 1981), rapid 
upward titration of neuroleptics (Sandy and 
Lacono, 1986), physical exhaustion, dehydration 
and underlying organic brain disorders (Guze an 
Baxter, 1985)" 
The exact pathogenesis of NMS is not 
clear but there is evidence in favour of the hy-
pothesis that NMS develops as a result of func-
tional dopaminergic deficit in striaral and 
hypothalamic areas (Lazarus et al 1989: Mann 
etal. 1991). Bromocriptine, a dopamine agonist 
and ECT which increase catecholamine levels 
including dopamine gives support to the above 
hypothesis (Grecnberg and Gujavarty, 1985). 
However there are other theories which have 
been put forward to explain the pathophysiology 
of NMS such a hypermetabolic state in muscles 
(May et al 1983) and sympathoadrcnomedullary 
hyperacticivity (Fie bel amd Schiffer. 1981). Also, 
it has been documented that treatment modalities 
which increase dopamine levels at post synaptic 
sites are not always effective (Greenberg and 
Gujavarty, 1985). It could be argued therefore 
that there may be more than one etiological 
expnanation for the development of NMS. 
No complications were seen in either of 
the present cases except for a sacral bed sore in 
the first case. A favourable outcome and decline 
in mortality due to cardio-respiratory or acute 
ren ' failure and have also been reported in recent 
siMJij-i (Shalev et al., 1989; et al 1990; Keck et 
al., i«91). 
TV present work underlines the need to 
minimise the risk factors, identify the syndrome 
early, stop the offending neuroleptic and institute 
intensive medical care ,and specific treatment 
with bromocriptine and/ or ECT to prevent the 
lethal complications. 
REFERENCES 
Delay, J and Deniker, P. (1968) Drug 
induced extra - pyramidal syndrome. In Vinken, 
P.J., Bruyn, G.W (Eds) Hand book of Clinical 
Neurology (Vol.6), Dieases of Basal Ganglia 
Amsterdam : North Holland publishig 248 266. 
Deng, M.Z., Chen, G.Q.and Phillips. 
M.R. (1990) Neuroleptic Malignant syndrome in 
12 of 9792 Chinese in-patients exposed t-;i 
neuroleptics; A prospective study. America;J 
Journal of Psychiatry, 147, 1149-1155. 
Fiebel, J.H., and Schiffer, R.B. (198); 
SympathoadrenomeduHary hyperactivity in 
neuroleptic malignant syndrome : A case report 
American Journal of Psychiatry
7, 46,115-116. 
Friendman, J.H.Feiberg. S.S. and 
Feldman, R.G. (1985) A neuroleptic malignant 
like syndrome due to levodopa therapy with-
drawal. Journal of Association of Physicians of 
India, 254.2792-2795. 
Greenberg, L.B. ;and Gujavarty, K. 
(1985) The neuroleptic malignant syndrome: Re-
port of three cases. Comprehensive Psychiatry 
20,63-70. 
Guze. B.H. and Baxter, L.R.(1985> 
Neuroleptic Malignant Syndrome. New England 
Journal of Medicine, 313, 163-166. 
Henderson, V.W and Wosten, G.F. 
(1981) Neuroleptic Malignant Syndrome: A path-
ogenic role of dopamine receptor blockade. Neu 
rology, 31,132-137. 
.lessee, S.S. and Andersen, G.F. (1983) 
Electro convulsive therapy in the neuroleptic 
malignant syndrome: Case reoprt. Clinical Psy-
chiatry, 44, 186-188. 
Kech. P.E., Pope, H.G. and Mc Elroy, 
S.L. (1991) Declining frequency of neuroleptic 
malignant syndrome in hospital population 
Americal Journal of Psychiatry, 148, 880-882. 
102 NEUROLEPTIC MALIGNANT SYNDROME 
Kurien, T., Rajeev, K.K., Abraham, 
O.C., Archana, S.and Cherian, A.M. (1993) 
Management of Neuroleptic Malignant Syndrome 
- A series of eight cases. Joumal of Association 
of Physicians of India, 41, 91-93. 
Kurlan, R., Hamill, R.and Shoulson, I 
(1984) Neuroleptic malignant syndrome. Clinical 
Neuropharmacology, 7, 109-120. 
Lazarus, A, Mann, S.C. and CarofF, 
S.N. (1989) The neuroleptic malignant syndrome 
and related conditions. Washington, D.C. Amer-
ican Psychiatric Press Inc. 
Levenson, J.L. (1985) Neuroleptic ma-
lignant syndrome. American Joumal of Psychia-
try, 142, 1137-1145. 
Mann, S.C, CarofF, S.N. and Lazarus, 
A (1991) Pathogensis of neuroleptic malignant 
syndrome, Psychiatric Annals, 21, 175-180. 
May, Morris, S.W.,Stewart,R.M., 
Fenton, B J., Gaffney, FA. (1983) Neuroleptic 
malignant syndrome - Response to dantrolene. 
Annals of Internal Medicine, 98,183 - 184. 
Sandy, K.R. and Lacono, R.P. (1986) 
Neuroleptic malignant syndrome. Journal of the 
American Medical Association, 225, 2291-2292. 
Shalev, A., Hermesh, H. and Munitz, H. 
(1989) Mortality from neuroleptic malignant syn-
drome. Journal of Clinical Psychiatry, 50, 18-
25. 
Singh, G.( 1981) The malignant neuroleptic 
syndrome- A review with report of three cases. 
Indian Journal of Psychiatry, 23, 179-183. 
Stanley, N.C. and Stephen, CM. (1993) 
Neuroleptic malignant syndrome. Medical Clin-
ics of North America, 77,185-202. 
Weinberger, D. and Kelly, M. (1977) 
Catatonia and malignant syndrome - A possible 
complication of neuroleptic administration. Jour-
nal of Nervous and Mental Disease, 165, 263-
268. 
R.C. Sharma*, MD, Assistant Professor in Psychiatry; S.Thakur, MD, Assistant Professor 
in Medicine; Vijay Sharma, MD, Assistant Professor in Microbiology - Indira Gandhi 
Medical College, Shimla -171 001. 
"Correspondence. 
MANASA HOSPITAL, RAJAMUNDRY ORATION AWARD 
Nominations are called for from persons who have done distinguished work in any 
branch of Psychiatry or allied discipline, for the selection of Manasa Hospital, 
Rajahmundry Oration Award for the year 1996. 
For details please contact 
Dr. G Prasad Rao 
2-1-479/2, Sai Krishna Apartments 
Nallakunta, Hyderabad 500 044. 
103 